Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ovarian Function Suppression for Breast Cancer (OFS)
NCT07158021Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of leuprolide in breast cancer (3 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Proportion of participants with ultrasensitive estradiol concentration > 10 pg/ml at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
leuprolide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07158021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158021.